The 3 Most Overlooked Stocks Set for a Triple-Digit Comeback
Discover the hidden gems primed for a solid rebound in health care, consumer discretionary behavior, and communication Hidden treasures sometimes go overlooked in the busy world of financial markets. Here, attention is frequently drawn to the names with the most sparkle. The purpose of this piece…#hidden #fda #pfizer #seagen #alibabaclouds #yoy #alibaba #trendyol #aliexpress #ebita (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2024 Category: Consumer Health News Source Type: news
Peninsula VC adds more than $100 million, brings on former Pfizer exec as partner
The VC has raised more than $1 billion over the past year. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 17, 2024 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Drugmakers' low U.S. taxes belie their high sales
Tax day is here. While Americans are scrambling to file last minute returns, things are somewhat more complicated for corporations. Corporations are supposed to pay a nominal tax rate of 21%. But in recent years, the biggest pharmaceutical companies had an average effective tax rate of less than…#bradsetser #pfizer #elililly #evaluatepharma #setser #ireland #singapore #ameetsarpatwari #harvardmedicalschool #nature (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news
A two-decade bet on a biotech company turned into a roughly $8 billion windfall for investors in the Baker Bros. Advisors hedge fund after Pfizer bought Seagen
.#bakerbrosadvisors #pfizer #seagen (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news
U.S. drug makers see big profits
— but many pay taxes far below the corporate rate Drugmakers make big profits in the U.S. But many pay taxes far below the 21% corporate tax rate. Pfizer's effective tax rate is so low it's getting a big refund despite booking $59 billion in revenue. With Tax Day…#pfizer #sydneylupkin #sydney #bradsetser #evaluatepharma #ireland #singapore (Source: Reuters: Health)
Source: Reuters: Health - April 13, 2024 Category: Consumer Health News Source Type: news
The CDC just killed another right-wing Covid vaccine conspiracy theory
A new study out of the U.S. Centers for Disease Control and Prevention dispels a popular coronavirus-related conspiracy theory that’s been popular among right-wingers. For a while now, anti-vaxxers have pointed to highly publicized incidents of people — particularly, young people — suffering…#lebronjamesjr #damarhamlin #cdc #pfizer #lesliecooper #mayoclinic (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2024 Category: Consumer Health News Source Type: news
U.S. drug makers see big profits
— but many pay taxes far below the corporate rate Drugmakers make big profits in the U.S. But many pay taxes far below the 21% corporate tax rate. Pfizer's effective tax rate is so low it's getting a big refund despite booking $59 billion in revenue.#pfizer (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2024 Category: Consumer Health News Source Type: news
2 Defensive Stocks to Buy Now as'Higher For Longer' Woes Rattle Markets
U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.#treasury #pfizer #apple (Source: Reuters: Health)
Source: Reuters: Health - April 11, 2024 Category: Consumer Health News Source Type: news
Pfizer RSV Shot Meets Goals in Trial Of High-risk Adults Under Age 60 Pfizer RSV Shot Meets Goals in Trial Of High-risk Adults Under Age 60
Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 9, 2024 Category: Allergy & Immunology Tags: Infectious Diseases Source Type: news
Young Adults May Soon Be Able to Get an RSV Shot
Pfizer Inc.’s RSV shot produced immune reactions in young adults at higher risk of severe illness just as well as in older people, spurring the company’s plans to apply for wider U.S. approval.
A single dose of the vaccine, called Abrysvo, produced a strong immune response in adults ages 18 to 59 with conditions such as asthma, diabetes, or chronic lung disease, Pfizer said. Based on the final-stage trial results, the company plans to ask the Food and Drug Administration to extend the shot’s approval to adults 18 and older.
[time-brightcove not-tgx=”true”]
RSV, or respiratory syncytial ...
Source: TIME: Health - April 9, 2024 Category: Consumer Health News Authors: Madison Muller and Robert Langreth/Bloomberg Tags: Uncategorized healthscienceclimate wire Source Type: news
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made Griffin one of the wealthiest people in the world, with a net worth of nearly $37 billion.…#kengriffin #griffin #understandably #pfe #pfizer #q4 #citadel #keithspeights (Source: Reuters: Health)
Source: Reuters: Health - April 9, 2024 Category: Consumer Health News Source Type: news
ViiV Healthcare Announces U.S. FDA Approval of Dovato (dolutegravir/lamivudine) for Adolescents Living with HIV
Durham, NC, April 8, 2024– ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the U.S. Food and Drug Administration (FDA) approved Dovato... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 8, 2024 Category: Drugs & Pharmacology Source Type: news
3 No-Brainer Dividend Stocks to Buy in April
Three Motley Fool contributors have dividends on their minds as the second quarter of 2024 begins. And they think they've found some no-brainer dividend stocks to buy in April. Here's why they like AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). One of the most…#abbvie #gileadsciences #gild #pfe #keithspeights #abbottlabs #dividendking #abbott #humira #rinvoq (Source: Reuters: Health)
Source: Reuters: Health - April 6, 2024 Category: Consumer Health News Source Type: news
Pfizer's Own Study Confirms Paxlovid Sucks
Pfizer's Own Study Confirms Paxlovid Sucks A Pfizer-funded, peer-reviewed paper authored by Pfizer scientists reveals that the company's antiviral COVID medication Paxlovid completely sucks, confirming what everyone's known since it came out. In a randomized phase 2-3 trial of the drug conducted…#pfizer #epochtimes #vinayprasad #rajeshgandhi #martinhirsch (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2024 Category: Consumer Health News Source Type: news
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
Sometimes it is worth it to buy shares of companies on the dip, and sometimes it isn't. It all depends on whether there are good reasons to believe the company in question will bounce back, and if it will, there is arguably no better time to invest than when it is down. Thankfully, even in a bull…#teladochealth #nvax #novavax #prosperjuniorbakiny #motleyfool #pfizer #avoidlikeplague (Source: Reuters: Health)
Source: Reuters: Health - April 2, 2024 Category: Consumer Health News Source Type: news
